Abstracts tagged "Adalimumab"

Abstract Number: 1986 • 2018 ACR/ARHP Annual Meeting
Adalimumab:TNF Complexes Are Cleared More Efficiently By Human Osteoclasts Than Those with Etanercept through Fcg-Receptor Binding and Internalization
Bohdan P. Harvey, Joel Cohen-Solal and Zehra Kaymakcalan, Biologics, AbbVie Bioresearch Center, Worcester, MA
Background/Purpose: TNF-alpha (TNFa) has been shown to contribute to osteoclastogenesis (OCgenesis) independently and in conjunction with M-CSF or RANKL, two key cytokines involved in osteoclast…
Abstract Number: 2593 • 2018 ACR/ARHP Annual Meeting
Similar Efficacy and Safety of Biosimilar Candidate IBI303 and Reference Products of Adalimumab in Patients with Ankylosing Spondylitis : Results from a Randomized, Double-Blind, Phase III Study
Xu Huji¹, Li Zhijun², Wu Jian³, Xing Qian⁴, Guixiu Shi⁵, Li Juan⁶, Liu Xu⁷, Lijun Wu⁸, Li Xiaomei⁹, Tan Wenfeng¹⁰, Dongyi He¹¹, Bi Liqi¹², Li Hongbin¹³, Xiao Zhengyu¹⁴, Shuai Zongwen¹⁵, Li Xiaoxia¹⁶, Wang Yongfu¹⁷, Luo Li¹⁸, Zheng Yi¹⁹, Xiao Weiguo²⁰, Zhou Hui²¹, Lu Yushan²¹, Zheng Shirui²¹ and Wang Xiong²¹, ¹Shanghai Changzheng Hospital, Shanghai, China, ²The First Affiliated Hospital of Bengbu Medical College, Bengbu, China, ³The First Affiliated Hospital of Soochow University, Suzhou, China, ⁴Qingdao municipal hospital, Qingdao, China, ⁵The First Affiliated Hospital of Xiamen University, Xiamen, China, ⁶Nanfang Hospital, Southern Medical University, Guangzhou, China, ⁷Peking University People’s Hospitalv, Beijing, China, ⁸People's Hospital of Xinjiang Uygur Autonomous Region, Wulumuqi, China, ⁹Anhui Provincial Hospital, Hefei, China, ¹⁰Jiangsu Province Hospital, Nanjing, China, ¹¹Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, China, ¹²China-Japan Friendship Hospital, Changchun, China, ¹³The Affiliated Hospital of Inner Mongolia Medical University, Huhehaote, China, ¹⁴The First Affiliated Hospital of Shantou University Medical College, Shantou, China, ¹⁵The First Affiliated Hospital of Anhui Medical University, Hefei, China, ¹⁶Xuanwu Hospital Capital Medical University, Beijing, China, ¹⁷The First Affiliated Hospital of Baotou Medical College of Inner Mongolia University of Science & Technology, Baotou, China, ¹⁸The First Affiliated Hospital of XinJiang Medical University, Wulumuqi, China, ¹⁹Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China, ²⁰The First Hospital of China Medical University, Shenyang, China, ²¹Innovent Biologics (Suzhou) Co. Ltd, Shanghai, China
Background/Purpose: IBI303, an injection of recombinant human anti-tumor necrosis factor-α monoclonal antibody, is adalimumab biosimilar candidate. Physicochemical properties assessment and non-clinical studies showed the structure,…
Abstract Number: 224 • 2018 ACR/ARHP Annual Meeting
Risk of Venous Thrombotic Events in Rheumatoid Arthritis Patients Initiating Tofacitinib or Adalimumab
Huifeng Yun, Fenglong Xie, Lang Chen and Jeffrey R. Curtis, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Recent concern has been raised for a risk for venous thromboembolism (VTE) associated with janus kinase inhibitors among patients with RA who are already…
Abstract Number: 2173 • 2018 ACR/ARHP Annual Meeting
Budget Impact of Etanercept Versus Adalimumab for Treatment of Rheumatoid Arthritis in Biologic-Naïve Patients in the United Kingdom
Kateryna Onishchenko¹, Miriam Tarallo², Cinzia Curiale² and Stamatia Theodora Alexopoulos¹, ¹Consulting at McCann Health, London, United Kingdom, ²Pfizer, Rome, Italy
Background/Purpose: Etanercept and adalimumab are TNFα inhibitors, both indicated in the UK for the treatment of patients with moderate-to-severe active RA who had inadequate response…
Abstract Number: 2606 • 2018 ACR/ARHP Annual Meeting
Long-Term Inhibition of Radiographic Progression with Originator Adalimumab in Patients with Moderate to Severe Psoriatic Arthritis with or without Radiographic Damage at Baseline
Laura C. Coates¹, Philip J. Mease², Kun Chen³, Maja Hojnik⁴, Wendell Valdecantos³, Pranav Sheth⁵, Daniel Aletaha⁶ and Fabiana Ganz⁷, ¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Swedish Medical Centre and University of Washington, Seattle, WA, ³AbbVie Inc., North Chicago, IL, ⁴AbbVie, Ljubljana, Slovenia, ⁵Group Health Associates, Trihealth, Cincinnati, OH, ⁶Medical University of Vienna, Vienna, Austria, ⁷AbbVie AG, Baar, Switzerland
Background/Purpose: Adalimumab (ADA) inhibited radiographic progression in patients (pts) with moderate to severe PsA in the ADEPT study and its open label extension (OLE). These…
Abstract Number: 562 • 2018 ACR/ARHP Annual Meeting
Low Inflammation on Magnetic Resonance Imaging in Patients with Rheumatoid Arthritis That Achieved Sustained Clinical Remission on Adalimumab
Paul Emery¹, Gerd R. Burmester², Esperanza Naredo³, Ivan Lagunes Galindo⁴, Ying Zhang⁵, Xin Wang⁵, Maja Hojnik⁶ and Philip G. Conaghan⁷, ¹University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, ²Charité-University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany, ³Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie, North Chicago, IL, ⁶AbbVie, Ljubljana, Slovenia, ⁷University of Leeds, Leeds, United Kingdom
Background/Purpose: ACR and EULAR recommend bDMARD tapering in patients (pts) with rheumatoid arthritis (RA) who achieved stable clinical remission. Yet, there are limited systematically collected…
Abstract Number: 2188 • 2018 ACR/ARHP Annual Meeting
Regional Analysis of Impact of Participation in a Patient Support Program on Clinical Outcomes Among Patients with Rheumatoid Arthritis Receiving Adalimumab (Humira)
Filip van Den Bosch¹, Andrew Ostor², Patrick Zueger³, Meijing Wu³, Ivan Lagunes Galindo³ and Siegfried Wassenberg⁴, ¹Ghent University Hospital, Ghent, Belgium, ²Cabrini Medical Center, Melbourne, Australia, ³AbbVie Inc., North Chicago, IL, ⁴Rheumazentrum Ratingen, Ratingen, Germany
Background/Purpose: Patients (pts) receiving adalimumab for RA or other indications are offered participation in the AbbVie pt support program (PSP). This analysis assessed clinical outcomes…
Abstract Number: 2617 • 2018 ACR/ARHP Annual Meeting
Prolonged Effectiveness of a 12 Week Regimen of Biosimilar Adalimumab in Indian (Asian) Patients Suffering from Symptomatic Acute-Chronic Ankylosing Spondylitis (AS)
Arvind Chopra¹, Nagnath Khadke², Manjit Saluja³, Toktam Kainifard⁴ and Anuradha Venugopalan⁵, ¹Center for Rheumatic Diseases, Pune, India, ²Rheumatolgy, Consultant, Pune, India, ³Rheumatology, Research Co-ordinator, Pune, India, ⁴Rheumatology, Consultant research and Dietitian, Tehran, Iran (Islamic Republic of), ⁵Rheumatology, R & D, Lab, Center for Rheumatic Diseases, Pune, India
Background/Purpose: On regulatory approval in India, challenging socioeconomics and infection prone scenario compelled us to seek prolonged effectiveness of short term anti-TNF therapeutic regimen (Chopra…
Abstract Number: 576 • 2018 ACR/ARHP Annual Meeting
An Analysis of Early Introduction of Adalimumab and Subsequent Bio-Free Condition in the Patients with Rheumatoid Arthritis
Satoshi Ito¹, Yoichi Kurossawa^1,2, Eriko Hasegawa^1,2, Daisuke Kobayashi^1,2, Shinji Taniguhi¹, Asami Abe¹, Hiroshi Otani¹, Kiyoshi Nakazono¹, Akira Murasawa¹, Ichiei Narita² and Hajime Ishikawa¹, ¹Department of Rheumatology, Niigata Rheumatic Center, Shibata, Japan, ²Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
Background/Purpose: HOPEFUL-1 trial showed efficacy of combination therapy with adalimumab (ADA) plus methotrexate (MTX) in MTX naïve patients with active early rheumatoid arthritis (eRA). In…
Abstract Number: 2270 • 2018 ACR/ARHP Annual Meeting
Treatment of Refractory Cystoid Macular Edema to Conventional Immunosuppressive Therapy: Tocilizumab Vs Anti-TNF-Alpha. Multicenter Study of 59 Patients
José Luis Martín-Varillas¹, Belén Atienza-Mateo¹, Vanesa Calvo-Río², Monica Calderón Goercke², Diana Prieto Peña², Rosalía Demetrio-Pablo³, Javier Loricera³, Eva Peña Sainz-Pardo³, M. Victoria Hernández⁴, Alfredo Adan⁵, Marina Mesquida⁵, Santos Insua⁶, Jose M Herreras⁷, Olga Maíz⁸, Ana Blanco⁹, Myriam Gandía¹⁰, David Diaz-Valle¹¹, Lucía Martínez-Costa¹², Elia Valls-Pascual¹², Gisela Díaz-Cordovés¹³, Manuel Díaz-Llopis¹⁴, Inmaculada Calvo¹⁵, Ignacio Torre-Salaberri¹⁶, Antonio Atanes¹⁷, Luis Francisco Linares¹⁸, Marisa Hernández¹⁹, Emma Beltrán²⁰, Miguel Cordero-Coma²¹, Elena Aurrecoechea²², Félix Francisco²³, Raquel Almodóvar González²⁴, Oscar Ruiz Moreno²⁵, Fernando Jiménez-Zorzo²⁶, Joan Miquel Nolla²⁷, Consuelo Modesto²⁸, Enar Pons¹, Miguel Angel González-Gay³ and Ricardo Blanco¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ³Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁴Rheumatology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ⁵Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ⁶Rheumatology, Hospital Universitario Santiago de Compostela. La Coruña. Spain, La Coruña, Spain, ⁷Ophthalmology, Hospital Universitario, IOBA. Valladolid. Spain, Valladolid, Spain, ⁸Hospital Universitario Donostia. San Sebastian. Spain, San Sebastián, Spain, ⁹Ophtamology, Hospital Universitario Donostia. San Sebastian. Spain, San Sebastian, Spain, ¹⁰Rheumatology, Hospital Puerta del Mar. Cádiz. Spain, Cádiz, Spain, ¹¹Hospital Clínico San Carlos. Madrid. Spain, Madrid, Spain, ¹²Hospital Universitario Doctor Peset. Valencia. Spain, Valencia, Spain, ¹³Rheumatology, Hospital Regional Universitario de Málaga. Spain, Málaga, Spain, ¹⁴Hospital Universitario La Fe. Valencia. Spain, Valencia, Spain, ¹⁵Hospital Universitario La Fe, Valencia, Spain, ¹⁶Rheumatology, Hospital Universitario de Basurto. Bilbao. Spain, Bilbao, Spain, ¹⁷Complejo Hospitalario Universitario A Coruña. Spain, A Coruna, Spain, ¹⁸Rheumatology, Hospital Virgen de la Arrixaca. Murcia. Spain, Murcia, Spain, ¹⁹Ophthalmology, Hospital General Universitario de Valencia. Spain, Valencia, Spain, ²⁰Rheumatology, Hospital del Mar. Barcelona. Spain, Barcelona, Spain, ²¹Ophthalmology, Hospital de León. Spain, León, Spain, ²²Rheumatology, Hospital de Sierrallana, Torrelavega. Cantabria. Spain, Torrelavega, Spain, ²³Rheumatology, Hospital Doctor Negrín. Las Palmas de Gran Canaria. Spain, Las Palmas de Gran Canaria, Spain, ²⁴Rheumatology, Hospital Universitario Fundación Alcorcón. Madrid. Spain, Madrid, Spain, ²⁵Ophthalmology and Rheumatology, Hospital Miguel Servet. Zaragoza. Spain, Zaragoza, Spain, ²⁶Hospital Miguel Servet. Zaragoza. Spain, Zaragoza, Spain, ²⁷Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²⁸Hospital Universitari Vall d'Hebron. Barcelona. Spain, Barcenola, Spain
Background/Purpose: Cystoid macular edema (CME) is the main cause of irreversible visual loss in patients with uveitis. Our aim objective was to determine the efficacy…
Abstract Number: 2621 • 2018 ACR/ARHP Annual Meeting
Predictors of Survival of Adalimumab Treatment in the Management of Ankylosing Spondylitis and Psoriatic Arthritis in Canadian Routine Care
Louis Bessette^1,2, Majed Khraishi³, Jacqueline Stewart^4,5, Andrew Chow^6,7, Viktoria Pavlova⁸, Brandusa Florica^6,9 and Valencia P. Remple^10,11, ¹Centre Hospitalier de l'Université Laval, Quebec, QC, Canada, ²Rheumatology, Laval University, Quebec, QC, Canada, ³Memorial University of Newfoundland, St. John's, NF, Canada, ⁴Penticton Regional Hospital, Penticton, BC, Canada, ⁵University of British Columbia, Penticton, BC, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷Trillium Health Partners Credit Valley Hospital, Mississauga, ON, Canada, ⁸McMaster University, Hamilton, ON, Canada, ⁹Trillium Health Partners, Mississauga, ON, Canada, ¹⁰AbbVie Corporation, Montreal, QC, Canada, ¹¹School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Biologics therapy survival is often used as a proxy for treatment effectiveness and safety. However, it may be influenced by patient characteristics, utilization patterns,…
Abstract Number: 612 • 2018 ACR/ARHP Annual Meeting
Anti-Drug Antibodies Detected By Competitive ELISA Can Predict Treatment Failure in Patients Taking Adalimumab
Manca Ogrič¹, Polona Žigon¹, Katja Lakota^1,2, Sonja Praprotnik¹, David Drobne^3,4, Borut Štabuc^3,4, Snezna Sodin Semrl^1,2 and Saša Čučnik^1,5, ¹University Medical Centre Ljubljana, Department of Rheumatology, Ljubljana, Slovenia, ²University of Primorska, Faculty of Mathematics, Natural Science and Information Technology, Koper, Slovenia, ³University Medical Centre Ljubljana, Department of Gastroenterology, Ljubljana, Slovenia, ⁴University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia, ⁵University of Ljubljana, Faculty of Pharmacy, Ljubljana, Slovenia
Background/Purpose: A reduced clinical response in patients taking TNF-alpha inhibitors is influenced by their immunogenicity and therefore the importance of therapeutic drug monitoring has been…
Abstract Number: 2380 • 2018 ACR/ARHP Annual Meeting
The Safety Profile of Adalimumab across Geographic Regions and Dosing Administrations Among Patients with Juvenile Idiopathic Arthritis Enrolled in a Registry
Hermine I. Brunner¹, Nicola Ruperto², Kabita Nanda³, Mary Toth⁴, Ivan Foeldvari⁵, John F. Bohnsack⁶, Diana Milojevic⁷, Daniel J Kingsbury⁸, Katherine A. Marzan⁹, Elizabeth Chalom¹⁰, Gerd Horneff¹¹, Rolf M. Kuester¹², Jason A Dare¹³, Maria Trachana¹⁴, Mareike Bereswill¹⁵, Hartmut Kupper¹⁵, Daniel J Lovell¹⁶ and Alberto Martini², ¹PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Gaslini Institute and Pediatric Rheumatology International Trials Organisation, Genoa, Italy, ³Seattle Children's Hospital, Seattle, WA, ⁴Nemours Children’s Hospital, Orlando, FL, ⁵Hamburg Center for Pediatric and Adolescent Rheumatology, Hamburg, Germany, ⁶University of Utah, Salt Lake City, UT, ⁷Johns Hopkins All Children’s Hospital, St. Petersburg, FL, ⁸Randall Children’s Hospital, Portland, OR, ⁹Children's Hospital Los Angeles, Los Angeles, CA, ¹⁰The Pediatric Specialty Center at Saint Barnabas, West Orange, NJ, ¹¹Asklepios Children's Clinic, Sankt Augustin, Germany, ¹²Orthopädiezentrum Altona, Hamburg, Germany, ¹³Arkansas Children’s Hospital, Little Rock, AR, ¹⁴Hippokration General Hospital, Aristotle University, Thessaloniki, Greece, ¹⁵AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ¹⁶PRCSG, Cincinnati Children’s Hospital Medical Center, Cinncinnati, OH
Background/Purpose: Adalimumab (ADA) has been approved for the treatment of polyarticular juvenile idiopathic arthritis (pJIA) with long-term use often required to maintain disease control. The…
Abstract Number: 2825 • 2018 ACR/ARHP Annual Meeting
Reduction of Antidrug Antibody Levels after Switching to Rituximab in Patients with Rheumatoid Arthritis with Previous Failure to Infliximab or Adalimumab
Ana Martínez^1,2, Chamaida Plasencia^2,3, Victoria Navarro-Compán², Borja Hernández-Breijo², Dora Pascual-Salcedo², Pilar Nozal⁴, Cristina Diego⁴, Irene Monjo^2,3, Laura Nuño^3,5 and Alejandro Balsa^2,6, ¹Immunology. La Paz University Hospital, Madrid, Spain, ²Immuno-Rheumatology research group, IdiPaz. La Paz University Hospital, Madrid, Spain, ³Rheumatology, La Paz University Hospital, Madrid, Spain, ⁴La Paz University Hospital, Immunology, Madrid, Spain, ⁵Immuno-Rheumatology research group, IdiPaz. La Paz University Hospital, madrid, Spain, ⁶Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: Rituximab (Rtx) induces transient depletion of B cells. Previous data showed that Rtx is particularly effective on autoimmune diseases in which auto-antibodies (auto-Ab) are…
Abstract Number: 693 • 2018 ACR/ARHP Annual Meeting
Combining Adalimumab with Methotrexate Does Not Improve Long Term Sustainability in Patients with Psoriatic Arthritis. Real World Evidence Report from the Quebec Database Rhumadata®
Omar Benryane¹, Louis Coupal² and Denis Choquette², ¹Médecine, Faculté de Médecine de l’Université de Montréal, Montréal, QC, Canada, ²Rheumatology, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada
Background/Purpose: Psoriatic Arthritis (PsA) in a musculoskeletal inflammatory condition associated with psoriasis. It has a heterogeneous set of clinical manifestations which include peripheral arthritis, axial…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].